Roivant Sciences (ROIV) Total Liabilities (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Total Liabilities came in at $416.3 million in Q1 2026, up 66.68% YoY from $249.7 million in Q1 2025, and up 65.75% on a QoQ basis from $251.1 million in Q4 2025.
Roivant Sciences (ROIV) Total Liabilities (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Total Liabilities data on file, last reported at $416.3 million in Q1 2026.
- Quarterly Total Liabilities rose 66.68% year-over-year to $416.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $416.3 million (up 66.68% YoY) and the FY2026 annual result came in at $416.3 million, up 66.68% from the prior year.
- Total Liabilities climbed to $416.3 million in Q1 2026, from $251.1 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $822.5 million in Q2 2022 to a low of $216.7 million in Q2 2025.
- A 5-year average of $560.3 million and a median of $626.0 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 73.21% — and 2025, when it plunged 67.73%.
- Tracing ROIV's Total Liabilities over 5 years: stood at $775.8 million in 2022, then decreased by 6.15% to $728.1 million in 2023, then sank by 64.79% to $256.4 million in 2024, then declined by 2.04% to $251.1 million in 2025, then jumped by 65.75% to $416.3 million in 2026.
- The last three Total Liabilities figures came in at $416.3 million (Q1 2026), $251.1 million (Q4 2025), and $257.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 384.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 384.62 Mn |
| Mar 31, 2026 | 416.28 Mn |
| Dec 31, 2025 | 251.14 Mn |
| Sep 30, 2025 | 257.14 Mn |
| Jun 30, 2025 | 216.70 Mn |
| Mar 31, 2025 | 249.74 Mn |
| Dec 31, 2024 | 256.38 Mn |
| Sep 30, 2024 | 625.99 Mn |
| Jun 30, 2024 | 601.16 Mn |
| Mar 31, 2024 | 773.95 Mn |
| Dec 31, 2023 | 728.10 Mn |
| Sep 30, 2023 | 739.91 Mn |
| Jun 30, 2023 | 802.51 Mn |
| Mar 31, 2023 | 782.02 Mn |
| Dec 31, 2022 | 775.82 Mn |
| Sep 30, 2022 | 701.39 Mn |
| Jun 30, 2022 | 822.52 Mn |
| Mar 31, 2022 | 523.70 Mn |
| Dec 31, 2021 | 529.62 Mn |
| Sep 30, 2021 | 652.01 Mn |